Who is eligible for clinical trial NCT06395467?

Participants must meet the protocol's inclusion criteria for Alcohol Use Disorder. The stated age range is 14 Years to 21 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06395467 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-03-04

Integrated Treatment for Enhancing Growth in Recovery During Adolescence (NCT06395467)

Integrated Treatment for Enhancing Growth in Recovery During Adolescence (InTEGRA)

🟢 Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: Massachusetts General Hospital

🩺 Plain-English Summary (8th-Grade Level)

This is a Phase II parallel group randomized controlled trial with 294 adolescents (age: 14-21 years) with alcohol and other drug \[AOD\] use disorder (hereafter substance use disorder), that compares two different active psychosocial interventions designed to address adolescent substance use disorder. Participants are recruited from our clinical settings and the community at two sites: one in the metro Boston, Massachusetts (MA) area and the other in the metro Farmington, Connecticut (CT), area. Study aims and hypotheses are as follows: 1. To extend the evidence for the initial efficacy of Integrated Treatment for Enhancing Growth in Recovery During Adolescence (InTEGRA), which integrates 12-Step Facilitation (TSF) with Motivational Enhancement Therapy/Cognitive Behavioral Therapy (MET/CBT) relative to gold standard MET/CBT alone (N = 294). It is hypothesized that youth assigned to InTEGRA will have greater 12-step participation during and following treatment, higher abstinence rates, and fewer substance-related negative consequences. 2. Investigate the personal recovery capital (PRC) and social recovery capital (SRC) mechanisms of behavior change through which InTEGRA may confer benefits dynamically over time (e.g., PRC: motivation, self-efficacy, coping; SRC: 12-step involvement; social network changes). 3. Investigate moderators of InTEGRA's effects on outcomes across one-year follow-up (e.g., effect of age, network support for AOD use; psychiatric severity; age composition of 12-step meetings on substance use and substance-related consequences). It is hypothesized that higher network support for AOD use, abstinence motivation, and greater AOD severity, will have a better response to InTEGRA. 4. Explore barriers and facilitators to InTEGRA adoption and implementation across providers and system administrators within the context of a type I hybrid effectiveness-implementation research design.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (8 items) and avoid the listed exclusions (6 items).

Location: UConn Health — Farmington, Connecticut

Age range: 14 Years to 21 Years

🧪 Interventions in This Study

InTEGRA (BEHAVIORAL)
MET/CBT (BEHAVIORAL)

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

14-21 years old
SUD based on criteria from the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)
able to read and comprehend English at a 5th-grade level
residence in Eastern time zone states (Connecticut, Delaware, Florida, Georgia, Indiana, Kentucky, Maine, Maryland, Massachusetts, Michigan, New Hampshire, New Jersey, New York, North Carolina, Ohio, Pennsylvania, Rhode Island, South Carolina, Tennessee, Vermont, Virginia, and West Virginia
any AOD use in the past 90 days (or in the 90 days prior to being in a controlled environment)
meet patient placement criteria for level I (outpatient) treatment
participant and a family member/guardian responsible for providing collateral information (for those \<18 years) agree to sign Institutional Review Board (IRB)-approved consent
participant and family member responsible for providing collateral information who could be contacted in case the subject became lost to follow-up.

Usually NOT eligible if any of the following apply:

Exclusion criteria:
suicidal ideation with a plan, suicidal behavior, a plan to hurt oneself or others, or a history of self-injurious behavior occurring in past 30 days
lifetime diagnosis of schizophrenia
current health condition (i.e., medical, psychiatric) that compromises participant's ability to attend outpatient treatment
demonstrate inability or unwillingness to identify a "locator" who could be contacted in case participant becomes lost to follow-up; or
youth attending another SUD treatment program or receiving psychotherapy that could conflict with study treatments.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (2 Sites)

UConn Health — Farmington, Connecticut
MGH Department of Psychiatry — Boston, Massachusetts

📞 Contact the Study Coordinator

Phone: (617) 724-5259

Email: aabry@mgh.harvard.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Alcohol Use Disorder

Observational Pilot Study to Explore the Social and Health Impacts of a New Model of Care in Oregon: Psilocybin Services on Alcoholism — Portland, Oregon
AAT for Alcohol Use Disorder in Veterans — San Diego, California
Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function — Eugene, Oregon
Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) — New Haven, Connecticut
Alcoholic Liver Disease and the Gut Microbiome — Los Angeles, California

Explore by condition: All Alcohol Use Disorder clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Contact the study coordinator using the phone/email above.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗